Open AccessMultiple Myeloma: What's New
Author(s) -
Durie Brian G. M.
Publication year - 2001
Publication title -
ca: a cancer journal for clinicians
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/canjclin.51.5.271
Subject(s) - multiple myeloma , disease , etiology , medicine , immunology , pathology
With conventional therapy, only 5% of multiple myeloma patients achieve complete response. But in recent clinical trials of high-dose therapy with autologous hematopoietic stem cell transplant, complete remission rates of 25-30% can be affected with median survival exceeding 5 years. Newer approaches in clinical trials, including more potent induction regimens utilizing thalidomide, alone or in combination with dexamethasone, are improving treatment outcomes. The authors suggest that potential for a cure now appears to be within reach.